Click here to download this poster
Click here to download this poster
Other resources:
-
Waiting room poster for health care offices
-
See announcement from Osteoporosis Canada
-
Read Understanding Pharmacare 101 to understand how Pharmacare Special Authority works in our province of BC
-
Provide patients with these template letters
-
Letter from Osteoporosis Canada for patients and caregivers
Letter from Ministry of Health
Subject: [External] Advance notification of Therapeutic Review of Drugs Used for the Primary Prevention of Osteoporosis
This is an advance notification that the Ministry of Health will soon be collecting patient input for our therapeutic review of drugs used for the primary prevention of osteoporosis. The drugs included in our review are as follows:
Generic names:
-
Oral bisphosphonates: etinodrate, alendronate 10mg and 70mg, alendronate/cholecalciferol, and risedronate;
-
Intravenous (IV) bisphosphonate: zoledronic acid;
-
Selective estrogen receptor modulators: raloxifene;
-
Biologic: denosumab
Brand names:
-
Oral bisphosphonates: generics;
-
Intravenous (IV) bisphosphonate: Aclasta®, generics;
-
Selective estrogen receptor modulators: Evista® and generics:
-
Biologic: Prolia®
Drugs used for: the primary prevention of osteoporosis
Tentative Dates for Input: Wednesday, October 20, 2021 to Wednesday, November 17, 2021 AT MIDNIGHT
You will receive an additional notification once the survey is available for input.
Once the survey is available for input we will also post a PDF of the survey questions so that patients, caregivers, and patient groups can review the questions before filling in the survey, itself.
Once the survey is posted, you can provide input by visiting our website at: http://www.health.gov.bc.ca/pharmacare/yourvoice/ .
Thank you,
Pharmaceutical, Laboratory & Blood Services Division - B.C. Ministry of Health